CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 338 enrolled
Drug / intervention
Omega 3 acid ethyl estersdietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01624727
NCT01624727N/ACompleted
CompareCT.gov

Slowing HEART diSease With Lifestyle and Omega-3 Fatty Acids (HEARTS)

Beth Israel Deaconess Medical Center·interventional·Posted Jun 21, 2012·Updated Sep 27, 2017

In Brief

A clinical study evaluating Omega 3 acid ethyl esters for Coronary Heart Disease and Metabolic Syndrome. Completed, enrolled 338 participants across 2 sites.

Detailed Summary

The purpose of the study is to target inflammation to reduce progression of noncalcified plaque in the coronary arteries using omega-3 fatty acid supplementation compared to standard of care.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Heart Disease, Metabolic Syndrome
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI), Tufts Medical Center

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 21, 2012
Enrollment StartJun 1, 2009
Primary CompletionJan 15, 2015
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 14.0 years ago

Interventions

Omega 3 acid ethyl estersdietary

Lovaza 3.6 g daily